A handful of issues concerning Sanofi Regeneron’s stock fell along with its biotech peers at the beginning of 2016, but it wasn’t long before more specific issues that continue to hound the company and its big pharma partner reared their ugly head. In March, patent litigation concerning the partners’ next-generation cholesterol-lowering drug, Praluent, drove down the stocks.